Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 25

Sort by

Sort Order Select

Journal Articles

A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Suthesh Sivapalaratnam, Steve Austin, Ulrike Lorch, Matej Goricar, Gillian Lowe, Ashley Gosnell, Prafull S. Gandhi, Joseph Vogel, Jigar Amin, Andrew Law, Benny Sorensen, Catherine Rea

Blood (2024) 144 (Supplement 1): 3953.1.

https://doi.org/10.1182/blood-2024-203782

Published: 2024

Journal Articles

A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

Suthesh Sivapalaratnam, Steve Austin, Ulrike Lorch, Thomas York, Andrew Want, Ashley Gosnell, Prafull S. Gandhi, Henrik Østergaard, Erik Bjornson, Tara O'Meara, Benny Sorensen, Roger E.G. Schutgens, Catherine Rea

Blood (2023) 142 (Supplement 1): 1225.

https://doi.org/10.1182/blood-2023-187279

Published: 2023

Journal Articles

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

K John Pasi, Pencho Georgiev, Tim Mant, Michael Desmond Creagh, Toshko Lissitchkov, MD, David Bevan, Steve Austin, Charles R Hay, Brigit Brand, Rashid Kazmi, Pratima Chowdary, Margaret V Ragni, Jihong Chen, Akin Akinc, Benny Sorensen, Savita Rangarajan

Blood (2015) 126 (23): 551.

https://doi.org/10.1182/blood.V126.23.551.551

Published: 2015

Journal Articles

Antithrombin Reduction Corrected Thrombin Generation in Samples from Hemophilia A and B Patients with Inhibitors

Gili Kenet, Tami Livnat, Emma Fosbury, Pratima Chowdary, Alfica Sehgal, Akin Akinc, Benny Sorensen

Blood (2015) 126 (23): 552.

https://doi.org/10.1182/blood.V126.23.552.552

Published: 2015

Journal Articles

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results

Anita Hill, Jorg Taubel, Jim Bush, Anna Borodovsky, Noriyuki Kawahata, Helen Mclean, Christine Powell, Prasoon Chaturvedi, Garvin Warner, Pushkal Garg, Benny Sorensen

Blood (2015) 126 (23): 2413.

https://doi.org/10.1182/blood.V126.23.2413.2413

Published: 2015

Journal Articles

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

Benny Sorensen, MD PhD, Tim Mant, MD, Akin Akinc, PhD, Amy Simon, MD, Lauren Melton, Christian Lynam, Andrew Strahs, PhD, Alfica Sehgal, PhD, Renta Hutabarat, PhD, Prasoon Chaturvedi, PhD, Scott Barros, PhD, Akshay Vaishnaw, MD PhD, Aln-AT Investigators

Blood (2014) 124 (21): 693.

https://doi.org/10.1182/blood.V124.21.693.693

Published: 2014

Journal Articles

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

Anna Borodovsky, PhD, Kristina Yucius, Andrew Sprague, Nirmal K Banda, PhD, V. Michael Holers, MD, Akshay Vaishnaw, MD PhD, Martin Maier, PhD, Rajeev Kallanthottathil, PhD, Klaus Charisse, PhD, Satya Kuchimanchi, PhD, Muthiah Manoharan, PhD, David J Salant, MD, Kevin Fitzgerald, PhD, Rachel Meyers, PhD, Benny Sorensen, MD PhD

Blood (2014) 124 (21): 1606.

https://doi.org/10.1182/blood.V124.21.1606.1606

Published: 2014

Journal Articles

Recombinant Factor VIII Combined With Recombinant Von Willebrand Factor In Patients With Severe Hemophilia A: A Prospective Clinical Study Of Safety and Pharmacokinetics

Toshko Lissitchkov, Jerzy Windyga, Barbara A. Konkle, Wolfgang Draxler, Miranda Chapman, Wing-Yen Wong, Benny Sørensen, Bruce M. Ewenstein

Blood (2013) 122 (21): 336.

https://doi.org/10.1182/blood.V122.21.336.336

Published: 2013

Journal Articles

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives

Guy Young, Benny Sørensen, Yesim Dargaud, Claude Negrier, Kathleen Brummel-Ziedins, Nigel S. Key

Blood (2013) 121 (11): 1944–1950.

https://doi.org/10.1182/blood-2012-08-378935

Published: 2013

Journal Articles

Biological Explanation of Clinically Observed Elevation of TFPI Plasma Levels After Treatment with TFPI-Antagonistic Aptamer BAX 499

Michael Dockal, PhD, Robert Pachlinger, Rudolf Hartmann, PhD, Sabine Knappe, PhD, Benny Sorensen, Wing Yen Wong, Maureen Conlan, Michael Cecerle, Bruce M. Ewenstein, MD PhD, Hartmut J. Ehrlich, MD, Friedrich Scheiflinger, PhD

Blood (2012) 120 (21): 1104.

https://doi.org/10.1182/blood.V120.21.1104.1104

Published: 2012

Journal Articles

Solulin increases clot stability in whole blood from humans and dogs with hemophilia

Jonathan H. Foley, Karl-Uwe Petersen, Catherine J. Rea, Lori Harpell, Sandra Powell, David Lillicrap, Michael E. Nesheim, Benny Sørensen

Blood (2012) 119 (15): 3622–3628.

https://doi.org/10.1182/blood-2011-11-392308

Published: 2012

Journal Articles

Fibrinogen: A Procoagulant and An Anticoagulant

Catherine J Rea, MB, Benny Sorensen, MD, Ph.D, Jørgen Ingerslev, MD, Peter Laursen

Blood (2011) 118 (21): 384.

https://doi.org/10.1182/blood.V118.21.384.384

Published: 2011

Journal Articles

Inter and Intra-Individual Variation of Factor VIII Half-Life In Severe Haemophilia A

Louise M Anthony, Catherine J Rea, MA, MRCP, Benny Sorensen, MD, Ph.D

Blood (2010) 116 (21): 544.

https://doi.org/10.1182/blood.V116.21.544.544

Published: 2010

Journal Articles

Reversal of Glanzmann's Thrombasthenia & Glycoprotein IIb/Iiia Antagonists by Combined Haemostatic Intervention with Fibrinogen Concentrate and Recombinant Factor VIIa.

Gayathri Murali-Krishnan, BSc, MSc, David Bevan, Consultant, Aine McCormick, Ph.D., Savita Rangarajan, MBBS, FRCP, FRCPath, Benny Sørensen, MD, Ph.D.

Blood (2009) 114 (22): 1325.

https://doi.org/10.1182/blood.V114.22.1325.1325

Published: 2009

Journal Articles

Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.

Benny Sørensen, MD, Ph.D., Yesim Dargaud, Gili Kenet, MD, PhD, Jeanne M. Lusher, MD, Andrew Mumford, Steven W. Pipe, MD, Andreas Tiede, MD, PhD

Blood (2009) 114 (22): 4443.

https://doi.org/10.1182/blood.V114.22.4443.4443

Published: 2009

Journal Articles

Pharmacokinetics, Coagulation Factor Consumption, and Product Efficacy in Patients Crossing Over from Full-Length FVIII to B-Domain Deleted R-FVIII and Back to Full-Length FVIII.

Catherine J Rea, MA, MRCP, Alex Dunkerley, BA, Benny Sorensen, MD, Ph.D., Savita Rangarajan, MBBS, FRCP, FRCPath

Blood (2008) 112 (11): 2269.

https://doi.org/10.1182/blood.V112.11.2269.2269

Published: 2008

Journal Articles

Recombinant Factor VIIa Combined with Fibrinogen Corrects the Coagulopathy Associated with Cardiopulmonary Bypass Surgery Ex Vivo

Pall T. Onundarson, M.D., Hanna S. Asvaldsdottir, M.Sc., Brynja R. Gudmundsdottir, M.Sc., Benny Sorensen, M.D., Ph.D.

Blood (2008) 112 (11): 4097.

https://doi.org/10.1182/blood.V112.11.4097.4097

Published: 2008

Journal Articles

Fibrinogen Concentrate Corrects Dilutional Coagulopathy: A Prospective, Randomized Placebo Controlled Clinical Trial.

Christian Fenger-Eriksen, MD, Tommy Midtgaard Jensen, Bo Kristensen, Klaus Møller Jensen, Else Tønnesen, Jørgen Ingerslev, MD, Benny Sorensen, M.D., Ph.D.

Blood (2008) 112 (11): 1227.

https://doi.org/10.1182/blood.V112.11.1227.1227

Published: 2008

Journal Articles

Thrombelastographic Whole Blood Coagulation Parameters Demonstrate Improved Clot Strength Induced by Tranexamic Acid during Cardiopulmonary Bypass.

Benny Sørensen, MD, PhD, Thomas D. Christensen, MD, PhD, Mogens Harrits Jepsen, MD, Lars Folkersen, MD, Inge Severinsen, MD, Vibeke E. Hjortdal, MD, PhD, DMSc, Jørgen Ingerslev, MD, DMSc

Blood (2007) 110 (11): 3195.

https://doi.org/10.1182/blood.V110.11.3195.3195

Published: 2007

Journal Articles

Citrate Anticoagulant Artificially Masks the Hemostatic Effect of Recombinant Factor VIIA in Dilutional Coagulopathy.

Christian Fenger-Eriksen, MD, Jørgen Ingerslev, MD, DMSc, Else Tønnesen, MD, DMSc, Benny Sørensen, MD, PhD

Blood (2007) 110 (11): 3160.

https://doi.org/10.1182/blood.V110.11.3160.3160

Published: 2007

NARROW

A Phase 1/2 Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

A Phase 1/2, First-in-Human, Study to Investigate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of HMB-001 in Participants with Glanzmann Thrombasthenia

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Weekly and Monthly Dosing Results in Patients with Hemophilia A or B

Antithrombin Reduction Corrected Thrombin Generation in Samples from Hemophilia A and B Patients with Inhibitors

A Subcutaneously Administered Investigational RNAi Therapeutic (ALN-CC5) Targeting Complement C5 for Treatment of PNH and Complement-Mediated Diseases: Interim Phase 1 Study Results

A Subcutaneously Administered RNAi Therapeutic (ALN-AT3) Targeting Antithrombin for Treatment of Hemophilia: Interim Phase 1 Study Results in Healthy Volunteers and Patients with Hemophilia a or B

Aln-CC5, an Investigational RNAi Therapeutic Targeting C5 for Complement Inhibition

Recombinant Factor VIII Combined With Recombinant Von Willebrand Factor In Patients With Severe Hemophilia A: A Prospective Clinical Study Of Safety and Pharmacokinetics

Thrombin generation and whole blood viscoelastic assays in the management of hemophilia: current state of art and future perspectives

Biological Explanation of Clinically Observed Elevation of TFPI Plasma Levels After Treatment with TFPI-Antagonistic Aptamer BAX 499

Solulin increases clot stability in whole blood from humans and dogs with hemophilia

Fibrinogen: A Procoagulant and An Anticoagulant

Inter and Intra-Individual Variation of Factor VIII Half-Life In Severe Haemophilia A

Reversal of Glanzmann's Thrombasthenia & Glycoprotein IIb/Iiia Antagonists by Combined Haemostatic Intervention with Fibrinogen Concentrate and Recombinant Factor VIIa.

Strategies for Securing and Maintaining Predictable Efficacy with Recombinant Activated Factor VII in On-Demand Treatment of Haemophilia Patients with Inhibitors.

Pharmacokinetics, Coagulation Factor Consumption, and Product Efficacy in Patients Crossing Over from Full-Length FVIII to B-Domain Deleted R-FVIII and Back to Full-Length FVIII.

Recombinant Factor VIIa Combined with Fibrinogen Corrects the Coagulopathy Associated with Cardiopulmonary Bypass Surgery Ex Vivo

Fibrinogen Concentrate Corrects Dilutional Coagulopathy: A Prospective, Randomized Placebo Controlled Clinical Trial.

Thrombelastographic Whole Blood Coagulation Parameters Demonstrate Improved Clot Strength Induced by Tranexamic Acid during Cardiopulmonary Bypass.

Citrate Anticoagulant Artificially Masks the Hemostatic Effect of Recombinant Factor VIIA in Dilutional Coagulopathy.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only